

Risk factors for coronary heart disease in women with s Toronto Risk Factor Study

Arthritis and Rheumatism

48, 3159-3167

DOI: [10.1002/art.11296](https://doi.org/10.1002/art.11296)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Coronary heart disease (CHD) in lupus: round up the usual suspects?. <i>Lupus</i> , 2004, 13, 557-560.	0.8	3
2	Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2004, 3, 423-453.	2.5	160
3	Mortality studies in SLE: how far can we improve survival of patients with SLE. <i>Autoimmunity Reviews</i> , 2004, 3, 418-420.	2.5	19
4	Dyslipoproteinemia and premature atherosclerosis in pediatric systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2004, 6, 425-433.	2.1	26
5	Outcome measures in osteoarthritis: Randomized controlled trials. <i>Current Rheumatology Reports</i> , 2004, 6, 20-30.	2.1	54
6	Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events. <i>Arthritis and Rheumatism</i> , 2004, 50, 3947-3957.	6.7	273
7	Cardiac risk factor awareness and management in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 51, 983-988.	6.7	32
8	Systemic Lupus Erythematosus. <i>Circulation</i> , 2004, 110, 399-404.	1.6	242
9	Therapy Insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 423-430.	3.3	55
10	Stroke Complicating Systemic Immune Mediated Disorders. <i>Seminars in Cerebrovascular Diseases and Stroke</i> , 2005, 5, 21-27.	0.1	1
12	Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 823-838.	1.4	56
13	Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups. <i>Arthritis and Rheumatism</i> , 2005, 52, 2774-2782.	6.7	214
14	Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 53, 718-723.	6.7	42
15	Atherogenesis and autoimmune disease: the model of lupus. <i>Lupus</i> , 2005, 14, 687-690.	0.8	43
16	Disease modification and cardiovascular risk reduction: two sides of the same coin?. <i>Rheumatology</i> , 2005, 44, 1473-1482.	0.9	69
17	The management of pediatric systemic lupus erythematosus. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 82-92.	3.2	13
18	“Not only” but also“™: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. <i>Rheumatology</i> , 2005, 44, 1492-1502.	0.9	244
19	Premature Atherosclerosis in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 329-354.	0.8	82

#	ARTICLE	IF	CITATIONS
20	High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. <i>Lupus</i> , 2005, 14, 576-582.	0.8	81
21	Exploring the Links Between Systemic Lupus Erythematosus and Cancer. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 387-402.	0.8	27
22	Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006, 8, R183.	1.6	39
23	Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. <i>Lupus</i> , 2006, 15, 562-569.	0.8	74
24	Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2006, 35, 85-95.	0.6	45
25	Long-Term Prognosis and Causes of Death in Systemic Lupus Erythematosus. <i>American Journal of Medicine</i> , 2006, 119, 700-706.	0.6	278
27	The cardiovascular manifestations of rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2006, 18, 135-140.	2.0	15
28	Update on nonsteroidal anti-inflammatory drugs. <i>Current Opinion in Rheumatology</i> , 2006, 18, 221-226.	2.0	26
29	Update on the treatment of lupus nephritis. <i>Kidney International</i> , 2006, 70, 1403-1412.	2.6	97
30	Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. <i>Autoimmunity Reviews</i> , 2006, 6, 48-53.	2.5	53
31	The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 1283-1290.	6.7	25
32	Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2220-2227.	6.7	105
33	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , 2006, 55, 892-899.	6.7	95
34	What do lupus specialists believe about managing conventional cardiovascular risk factors in patients with systemic lupus erythematosus?. <i>Lupus</i> , 2006, 15, 697-699.	0.8	4
35	Mycophenolate Mofetil: An Overview. <i>Lupus</i> , 2006, 15, 70-77.	0.8	3
36	Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. <i>Lupus</i> , 2006, 15, 675-682.	0.8	116
37	Lack of flow mediated dilation and enhanced angiotensin II-induced constriction in skeletal muscle arterioles of lupus-prone autoimmune mice. <i>Lupus</i> , 2006, 15, 326-334.	0.8	11
38	Metabolic syndrome in systemic lupus erythematosus: lower prevalence in Brazil than in the USA. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1542-1542.	0.5	14

#	ARTICLE	IF	CITATIONS
39	Endothelial function analysis and atherosclerotic risk factors in adolescents with systemic lupus erythematosus. <i>International Journal of Adolescent Medicine and Health</i> , 2007, 19, .	0.6	14
40	Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2007, 46, 76-80.	0.9	40
41	Subclinical carotid atherosclerosis in a patient with systemic lupus erythematosus. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 473-478.	3.2	1
42	The heart"joints connection: atherosclerosis and inflammation. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 517-529.	1.3	0
43	Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases?. <i>Lupus</i> , 2007, 16, 852-862.	0.8	22
44	Impaired endothelial function in systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 84-88.	0.8	48
45	Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2007, 46, 1551-1556.	0.9	54
46	Adherence with advice and prescriptions in SLE is mostly good, but better follow up is needed: A study with a questionnaire. <i>Lupus</i> , 2007, 16, 701-706.	0.8	23
47	Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. <i>Rheumatology</i> , 2007, 46, 1560-1565.	0.9	104
48	Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. <i>Lupus</i> , 2007, 16, 731-735.	0.8	85
49	Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. <i>Rheumatology</i> , 2007, 46, 983-988.	0.9	110
50	African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 618-622.	0.5	42
51	The Impact of Increased Body Mass Index on Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2007, 13, 128-133.	0.5	60
52	Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2007, 9, R84.	1.6	69
53	Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 618-626.	0.8	39
54	The second hit: comorbidities in systemic lupus erythematosus. <i>Future Rheumatology</i> , 2007, 2, 497-506.	0.2	3
55	Peripheral vascular disease in systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 720-723.	0.8	34
56	Systemic lupus erythematosus and exercise. <i>Lupus</i> , 2007, 16, 5-9.	0.8	64

#	ARTICLE	IF	CITATIONS
57	Lung cancer in systemic lupus erythematosus. <i>Lung Cancer</i> , 2007, 56, 303-306.	0.9	51
58	Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 631-638.	6.7	36
59	Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1384-1396.	6.7	108
60	Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 57, 845-850.	6.7	26
61	AthÃ©rome etÃ©lupus Ã©rythÃ©mateux systÃ©mique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 1235-1239.	0.0	0
62	Atheroma and systemic lupus erythematosus. <i>Joint Bone Spine</i> , 2007, 74, 566-570.	0.8	20
63	Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. <i>Clinical Rheumatology</i> , 2007, 26, 695-699.	1.0	33
64	The role of preventive cardiology in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2007, 9, 125-130.	2.1	18
65	A national study of the complications of lupus in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 127.e1-127.e6.	0.7	597
66	Evidence of Systemic Inflammation and Estimation of Coronary Artery Disease Risk: A Population Perspective. <i>American Journal of Medicine</i> , 2008, 121, S15-S20.	0.6	78
67	Pharmacotherapy of lupus nephritis: time for a consensus?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2099-2115.	0.9	3
68	EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 195-205.	0.5	645
69	Poor 1-Year Outcomes After Percutaneous Coronary Interventions in Systemic Lupus Erythematosus. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 201-208.	1.4	39
70	Arteriosclerosis obliterans associated with anti-cardiolipin antibody / Å2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2008, 47, 684-689.	0.9	24
71	Association of killer cell immunoglobulinâ€like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus. <i>Lupus</i> , 2008, 17, 793-798.	0.8	12
72	Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 258-265.	3.2	22
73	Functional Polymorphisms of Folate-Metabolizing Enzymes in Relation to Homocysteine Concentrations in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 2179-2186.	1.0	20
74	Systemic Lupus Erythematosus in a Multiethnic US Cohort, LUMINA (XLIX). <i>Journal of Clinical Rheumatology</i> , 2008, 14, 178-180.	0.5	4

#	ARTICLE	IF	CITATIONS
75	Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors. <i>Current Cardiology Reviews</i> , 2008, 4, 116-122.	0.6	87
76	Avalia��o do risco coronariano em mulheres com l��pus eritematoso sist��mico. <i>Revista Brasileira De Reumatologia</i> , 2009, 49, .	0.8	3
77	Inflammatory Disease Processes and Interactions with Nutrition. <i>British Journal of Nutrition</i> , 2009, 101, 1-45.	1.2	346
78	Cardiovascular disease complications in systemic lupus erythematosus. <i>Biomarkers in Medicine</i> , 2009, 3, 239-252.	0.6	17
79	Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. <i>Lupus</i> , 2009, 18, 508-515.	0.8	46
80	Pattern of Arterial Calcification in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 2212-2217.	1.0	45
81	Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality. <i>Lupus</i> , 2009, 18, 383-386.	0.8	17
82	Myocardial Perfusion Imaging in Assessing Risk of Coronary Events in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 288-294.	1.0	36
83	Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease. <i>Lupus</i> , 2009, 18, 313-317.	0.8	24
84	Cardiovascular risk assessment and treatment in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 481-494.	1.4	32
85	Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: A randomized placebo��controlled study. <i>Arthritis and Rheumatism</i> , 2009, 60, 1060-1064.	6.7	51
86	Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study. <i>Arthritis and Rheumatism</i> , 2009, 61, 1396-1402.	6.7	228
87	Atherosclerosis in Autoimmune Rheumatic Diseases��Mechanisms and Clinical Findings. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 37, 20-28.	2.9	65
88	Epidemiology of atherosclerosis in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009, 11, 248-254.	2.1	34
89	Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2009, 11, R186.	1.6	129
90	Developments in the clinical understanding of lupus. <i>Arthritis Research and Therapy</i> , 2009, 11, 245.	1.6	36
91	Vascular reactivity in patients with undifferentiated connective tissue diseases. <i>Atherosclerosis</i> , 2009, 203, 185-191.	0.4	12
93	Risk Factors for Development of Coronary Artery Disease in Women with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 2454-2461.	1.0	66

#	ARTICLE	IF	CITATIONS
94	Vitamin D in systemic lupus erythematosus: potential beyond bone health. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 297-309.	0.3	2
95	Lupus Nephritis. <i>American Journal of the Medical Sciences</i> , 2009, 337, 451-460.	0.4	32
96	The USPSTF Recommendation Statement on Coronary Heart Disease Risk Assessment. <i>Annals of Internal Medicine</i> , 2010, 152, 405.	2.0	0
97	Management of cardiovascular complications in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 75-100.	0.3	29
98	Lupus Registries: Evolution and Challenges. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 224-245.	1.6	16
99	Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. <i>Rheumatology</i> , 2010, 49, 691-696.	0.9	29
100	Characteristics and risk factors for hyperglycemia in Chinese female patients with systemic lupus erythematosus. <i>Lupus</i> , 2010, 19, 1344-1350.	0.8	10
101	Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients. <i>Lupus</i> , 2010, 19, 27-33.	0.8	27
102	Lupus Nephritis. , 2010, , 308-321.		4
103	Hydroxychloroquine and Glycemia in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 1136-1142.	1.0	124
104	Accumulation of VEGFR-2+/CD133+ cells and decreased number and impaired functionality of CD34+/VEGFR-2+ cells in patients with SLE. <i>Rheumatology</i> , 2010, 49, 63-72.	0.9	25
105	Risk factors for coronary heart disease in connective tissue diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010, 2, 145-153.	1.2	13
106	European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1269-1274.	0.5	308
107	Principles in Management of Systemic Lupus Erythematosus. , 2010, , 83-90.		0
108	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. <i>Journal of Rheumatology</i> , 2010, 37, 322-329.	1.0	83
109	The Metabolic Syndrome in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 81-97.	0.8	31
110	Oxidative stress and homocysteine metabolism in patients with lupus nephritis. <i>Lupus</i> , 2010, 19, 65-72.	0.8	37
111	Lupus nephritis: current update. <i>Arthritis Research and Therapy</i> , 2011, 13, 240.	1.6	133

#	ARTICLE	IF	CITATIONS
112	Perceptions and measurements of physical activity in patients with systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 231-242.	0.8	65
113	An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 1459-1465.	0.8	42
114	Study of endothelial dysfunction and its correlation with disease activity in systemic lupus erythematosus patients without conventional cardiovascular risk factors. <i>Indian Journal of Rheumatology</i> , 2011, 6, 178-184.	0.2	5
116	Atherosclerosis and Tissue Injury in Systemic Lupus Erythematosus. , 2011, , 513-522.		0
117	Dyslipidaemia in patients with lupus nephritis. <i>Nephrology</i> , 2011, 16, 511-517.	0.7	32
118	The Impact of Systemic Lupus Erythematosus on Women's Sexual Functioning. <i>Journal of Sexual Medicine</i> , 2011, 8, 3389-3397.	0.3	31
119	Systemic vascular diseases in the antiphospholipid syndrome. What is the best diagnostic choice?. <i>Autoimmunity Reviews</i> , 2011, 10, 235-237.	2.5	14
120	Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. <i>Nature Reviews Rheumatology</i> , 2011, 7, 399-408.	3.5	320
121	Alterations in Circulating Fatty Acid Composition in Patients with Systemic Lupus Erythematosus. <i>Journal of Parenteral and Enteral Nutrition</i> , 2011, 35, 198-208.	1.3	29
123	Ethnic differences in cardiovascular risk in rheumatic disease: focus on Asians. <i>Nature Reviews Rheumatology</i> , 2011, 7, 609-618.	3.5	9
124	Prevalence and risk factors for coronary artery calcification following kidney transplantation for systemic lupus erythematosus. <i>Rheumatology</i> , 2011, 50, 1659-1664.	0.9	14
125	Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 227-241.	1.3	88
126	Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 936-944.	0.8	19
127	Prevalence of and Factors Associated with Hypertension in Young and Old Women with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2011, 38, 1026-1032.	1.0	93
128	Longitudinal Evolution of Risk of Coronary Heart Disease in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 968-973.	1.0	18
129	25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2012, 51, 544-551.	0.9	77
130	A pilot study of office-based spirometry in patients with systemic lupus erythematosus. <i>Lupus</i> , 2012, 21, 1343-1350.	0.8	3
131	Cardiovascular event in systemic lupus erythematosus in northern Sweden: Incidence and predictors in a 7-year follow-up study. <i>Lupus</i> , 2012, 21, 452-459.	0.8	105

#	ARTICLE	IF	CITATIONS
133	Are Patients with Inflammatory Bowel Disease at Increased Risk of Coronary Artery Disease?. American Journal of Medicine, 2012, 125, 956-962.	0.6	49
134	Anti-phospholipid antibodies contribute to arteriosclerosis in patients with systemic lupus erythematosus through induction of tissue factor expression and cytokine production from peripheral blood mononuclear cells. Thrombosis Research, 2012, 130, 667-673.	0.8	24
135	Physical activity in patients with systemic lupus erythematosus and matched controls. Scandinavian Journal of Rheumatology, 2012, 41, 290-297.	0.6	36
136	Accelerated atherosclerosis in patients with SLE—mechanisms and management. Nature Reviews Rheumatology, 2012, 8, 214-223.	3.5	201
137	Cardiovascular Involvement in Systemic Lupus Erythematosus. , 2012, , .		1
138	Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus. Clinical Rheumatology, 2012, 31, 669-675.	1.0	21
139	Prevalence and correlation of conventional and lupus-specific risk factors for cardiovascular disease in Chinese systemic lupus erythematosus patients. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 95-101.	1.3	26
140	Uncertainty and Opportunities in Patients with Established Systemic Lupus Erythematosus: A Qualitative Study. Musculoskeletal Care, 2012, 10, 1-12.	0.6	37
141	Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus. Zeitschrift Fur Rheumatologie, 2013, 72, 172-177.	0.5	48
142	Early detection of premature subclinical coronary atherosclerosis in systemic lupus erythematosus patients. Egyptian Heart Journal, 2013, 65, 281-288.	0.4	3
143	Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand?. Lupus, 2013, 22, 1243-1250.	0.8	43
144	Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology, 2013, 52, 2048-2055.	0.9	65
145	Premature coronary heart disease in SLE: can we prevent progression?. Lupus, 2013, 22, 1232-1242.	0.8	31
146	The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. Seminars in Arthritis and Rheumatism, 2013, 43, 77-95.	1.6	281
147	Supervised physical exercise improves endothelial function in patients with systemic lupus erythematosus. Rheumatology, 2013, 52, 2187-2195.	0.9	45
148	Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus, 2013, 22, 1251-1258.	0.8	30
149	Metabolic syndrome in Chinese patients with systemic lupus erythematosus: no association with plasma cortisol level. Lupus, 2013, 22, 519-526.	0.8	16
150	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2013, 72, 1308-1314.	0.5	78

#	ARTICLE	IF	CITATIONS
151	An update on the management of comorbid conditions in lupus nephritis. <i>Clinical Investigation</i> , 2013, 3, 281-293.	0.0	0
152	Peripheral Vascular Disease in Systemic Lupus Patients. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 367-372.	0.5	13
153	Atherosclerosis in Systemic Lupus Erythematosus. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 62, 255-262.	0.8	62
154	Update on the treatment of lupus nephritis. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 224-230.	1.0	26
155	Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus. <i>Current Cardiology Reviews</i> , 2013, 9, 15-19.	0.6	43
156	Pathogenesis and Treatment of Atherosclerosis in Lupus. , 2013, , 341-351.		2
157	Alpha-Chlorofatty Acid and Coronary Artery or Aorta Calcium Scores in Women with Systemic Lupus Erythematosus. A Pilot Study. <i>Journal of Rheumatology</i> , 2014, 41, 1834-1842.	1.0	4
158	Are Microparticles the Missing Link between Thrombosis and Autoimmune Diseases? Involvement in Selected Rheumatologic Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 675-681.	1.5	13
159	Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1144-1150.	0.5	75
160	Tomography and blood vessels in Hughes syndrome. <i>Lupus</i> , 2014, 23, 337-341.	0.8	3
161	Metabolic Syndrome Is Correlated With Carotid Atherosclerosis in Patients With Lupus Nephritis. <i>American Journal of the Medical Sciences</i> , 2014, 348, 486-491.	0.4	12
162	Death causes and pathogens analysis of systemic lupus erythematosus during the past 26Âyears. <i>Clinical Rheumatology</i> , 2014, 33, 57-63.	1.0	98
163	Decreased circulating endothelial progenitor cells as an early risk factor of subclinical atherosclerosis in systemic lupus erythematosus. <i>Rheumatology</i> , 2014, 53, 631-638.	0.9	35
164	Pragmatic approaches to therapy for systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2014, 10, 97-107.	3.5	81
167	Prognostic value of flow mediated dilation in patients with systemic lupus erythematosus: A pilot prospective cohort study. <i>Atherosclerosis</i> , 2014, 236, 381-384.	0.4	10
168	Cardiovascular Comorbidity in Rheumatic Diseases. <i>Heart Failure Clinics</i> , 2014, 10, 339-352.	1.0	52
169	Improving cardiovascular outcomes in rheumatic diseases: Therapeutic potential of circulating endothelial progenitor cells. , 2014, 142, 231-243.		19
170	Pathogenesis and Treatment of Atherosclerosis in Lupus. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 475-495.	0.8	26

#	ARTICLE	IF	CITATIONS
171	Prevention and management of co-morbidities in SLE. <i>Presse Medicale</i> , 2014, 43, e187-e195.	0.8	25
172	Physical Activity Program Is Helpful for Improving Quality of Life in Patients with Systemic Lupus Erythematosus. <i>Tohoku Journal of Experimental Medicine</i> , 2015, 237, 193-199.	0.5	48
173	Clinical Characteristics of Systemic Lupus Erythematosus Patients with Coronary Artery Disease: A Matched Study. <i>Advances in Pharmacoepidemiology & Drug Safety</i> , 2015, 04, .	0.1	1
174	Short-term patient-centered nutrition counseling impacts weight and nutrient intake in patients with systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 1321-1326.	0.8	22
175	Developing new evaluation methods in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 479-488.	0.3	1
176	Metabolic syndrome in patients with systemic lupus erythematosus from South India. <i>Indian Journal of Rheumatology</i> , 2015, 10, 189-195.	0.2	2
177	Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: A cross-sectional study of two cohorts. <i>Lupus</i> , 2015, 24, 58-65.	0.8	21
178	Atherosclerotic Vascular Disease in the Autoimmune Rheumatologic Patient. <i>Current Atherosclerosis Reports</i> , 2015, 17, 497.	2.0	21
179	Sex-Specific Disparities in Risk Factors for Coronary Heart Disease. <i>Current Atherosclerosis Reports</i> , 2015, 17, 49.	2.0	22
180	When gout goes to the heart: does gout equal a cardiovascular disease risk factor?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 631-634.	0.5	35
181	Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. <i>Rheumatology</i> , 2015, 54, 1244-1249.	0.9	101
182	Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1373-1385.	1.0	21
183	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.5	70
184	Evolutionary Aspects of Electrocardiographic and Echocardiographic Manifestations in Systemic Lupus Erythematosus: Descriptive Longitudinal Study about 25 Cases in 18-Month Monitoring. <i>Journal of Clinical & Experimental Cardiology</i> , 2016, 7, .	0.0	0
185	Mechanisms of Vascular Damage in Systemic Lupus Erythematosus. , 2016, , 293-298.		0
186	Current and emerging treatment options in the management of lupus. <i>ImmunoTargets and Therapy</i> , 2016, 5, 9.	2.7	32
187	Effects of Long-Term Type I Interferon on the Arterial Wall and Smooth Muscle Progenitor Cells Differentiation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 266-273.	1.1	24
188	It hasn't gone away: the problem of glucocorticoid use in lupus remains. <i>Rheumatology</i> , 2016, 56, kew406.	0.9	43

#	ARTICLE	IF	CITATIONS
189	Cardiovascular risk in systemic lupus erythematosus. Revista Colombiana De Reumatología (English) Tj ETQq0 0 0 0 BT /Overlock 10 Tf	0.1	0
190	Endothelial progenitor cells: Are they displaying a function in autoimmune disorders?. Mechanisms of Ageing and Development, 2016, 159, 44-48.	2.2	13
191	Association of estimated sodium and potassium intake with blood pressure in patients with systemic lupus erythematosus. Lupus, 2016, 25, 1463-1469.	0.8	3
192	Riesgo cardiovascular en lupus eritematoso sistémico. Revista Colombiana De Reumatología, 2016, 23, 242-249.	0.0	2
194	Diagnosis and risk stratification of women with stable ischemic heart disease. Journal of Nuclear Cardiology, 2016, 23, 986-990.	1.4	4
195	Brief Report: Vitamin D Deficiency Is Associated With Endothelial Dysfunction and Increases Type I Interferon Gene Expression in a Murine Model of Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2016, 68, 2929-2935.	2.9	30
196	Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis. Arthritis Research and Therapy, 2016, 18, 306.	1.6	28
197	Cardiovascular risk and its modification in patients with connective tissue diseases. Best Practice and Research in Clinical Rheumatology, 2016, 30, 81-94.	1.4	12
198	Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology, 2016, 55, 1623-1630.	0.9	31
199	Subclinical arteriosclerosis and osteoprotegerin levels in a population with systemic lupus erythematosus in the south of Europe. Lupus, 2016, 25, 781-782.	0.8	1
200	Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review. Journal of Rheumatology, 2016, 43, 54-65.	1.0	67
201	Coronary, Carotid, and Lower-extremity Atherosclerosis and Their Interrelationship in Danish Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2016, 43, 315-322.	1.0	24
202	Defects in lysosomal maturation facilitate the activation of innate sensors in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2142-51.	3.3	70
203	Effects of a one-year physical activity programme for women with systemic lupus erythematosus " a randomized controlled study. Lupus, 2016, 25, 602-616.	0.8	41
204	Healthy lifestyle habits for patients with systemic lupus erythematosus: A systemic review. Seminars in Arthritis and Rheumatism, 2016, 45, 463-470.	1.6	44
205	Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus, 2016, 25, 177-184.	0.8	47
206	Prevalence of metabolic syndrome in a cohort of systemic lupus erythematosus patients from Northeastern Brazil: association with disease activity, nephritis, smoking, and age. Rheumatology International, 2016, 36, 117-124.	1.5	30
207	Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment. Lupus, 2017, 26, 529-536.	0.8	51

#	ARTICLE	IF	CITATIONS
208	The evolving concept of SLE comorbidities. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 753-768.	1.3	30
209	Role of Inflammatory Diseases in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 353-361.	1.0	11
210	Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. <i>Journal of Autoimmunity</i> , 2017, 82, 1-12.	3.0	132
211	Exercise and physical activity in systemic lupus erythematosus: A systematic review with meta-analyses. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 204-215.	1.6	93
212	Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. <i>Journal of Rheumatology</i> , 2017, 44, 1841-1849.	1.0	49
213	Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?. <i>Lupus Science and Medicine</i> , 2017, 4, e000212.	1.1	24
214	Comorbidity in Rheumatic Diseases. , 2017, , 1-31.		0
215	Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?. <i>Lupus</i> , 2017, 26, 1351-1367.	0.8	7
216	Clinical significance of lipid profile in systemic lupus erythematosus patients: Relation to disease activity and therapeutic potential of drugs. <i>Egyptian Rheumatologist</i> , 2017, 39, 93-98.	0.5	9
217	The relation between, metabolic syndrome and quality of life in patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2017, 12, e0187645.	1.1	16
218	Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2017, Volume 9, 191-200.	0.8	28
219	Atherosclerotic vascular disease in the autoimmune rheumatologic woman. <i>Clinical Cardiology</i> , 2018, 41, 258-263.	0.7	13
220	Clinical and laboratory aspects of dyslipidemia in Brazilian women with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2018, 37, 1539-1546.	1.0	15
221	Phenome-wide Association Studies Uncover a Novel Association of Increased Atrial Fibrillation in Male Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 1630-1636.	1.5	22
222	Impact of Diabetes Mellitus on the Risk of End-Stage Renal Disease in Patients with Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2018, 8, 6008.	1.6	16
223	Managing premature atherosclerosis in patients with chronic inflammatory diseases. <i>Cmaj</i> , 2018, 190, E430-E439.	0.9	6
224	Metabolic syndrome, autoimmunity and rheumatic diseases. <i>Pharmacological Research</i> , 2018, 133, 277-288.	3.1	71
225	Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants. <i>Clinical Rheumatology</i> , 2018, 37, 1521-1528.	1.0	8

#	ARTICLE	IF	CITATIONS
226	The association between metabolic syndrome and its components with systemic lupus erythematosus: a comprehensive systematic review and meta-analysis of observational studies. <i>Lupus</i> , 2018, 27, 899-912.	0.8	22
227	Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases. <i>Autoimmunity Reviews</i> , 2018, 17, 703-708.	2.5	76
228	Late-onset systemic lupus erythematosus: Is it "mild lupus"? <i>Lupus</i> , 2018, 27, 235-242.	0.8	22
229	Heart failure in systemic lupus erythematosus. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 187-197.	2.3	34
230	Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. <i>Nature Reviews Cardiology</i> , 2018, 15, 33-44.	6.1	50
231	QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000272.	1.1	22
232	Hypertension: Focus on autoimmunity and oxidative stress. <i>Free Radical Biology and Medicine</i> , 2018, 125, 104-115.	1.3	91
233	Increased serum leptin levels are associated with metabolic syndrome and carotid intima media thickness in premenopausal systemic lupus erythematosus patients without clinical atherosclerotic vascular events. <i>Lupus</i> , 2018, 27, 1509-1516.	0.8	13
234	Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. <i>Mediators of Inflammation</i> , 2018, 2018, 1-11.	1.4	56
235	Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. <i>Frontiers in Medicine</i> , 2018, 4, 262.	1.2	53
236	Incidence of cardiovascular risk factors in female patients with systemic lupus erythematosus: a 3-year follow-up cohort. <i>Lupus</i> , 2018, 27, 1790-1798.	0.8	8
237	Recognition and control of hypertension, diabetes, and dyslipidemia in patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2018, 37, 2693-2698.	1.0	7
238	Systemic lupus erythematosus and hypertension. <i>Autoimmunity Reviews</i> , 2019, 18, 102371.	2.5	50
239	25-Hydroxyvitamin D concentrations and risk of metabolic syndrome in systemic lupus erythematosus women. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 2067-2072.	0.9	3
240	Challenges in Cardiovascular Risk Prediction and Stratification in Women. <i>Cardiovascular Innovations and Applications</i> , 2019, 3, .	0.1	2
241	Predisposing factors to nonfatal cardiovascular events in women with systemic lupus erythematosus. An observational, cross-sectional, multicenter study in Spain from the risk/systemic lupus erythematosus thematic network. <i>Medicine (United States)</i> , 2019, 98, e17489.	0.4	4
242	Temporal relationships between systemic lupus erythematosus and comorbidities. <i>Rheumatology</i> , 2019, 58, 840-848.	0.9	41
243	Systemic Glucocorticoid Therapy for SLE. , 2019, , 661-672.		0

#	ARTICLE	IF	CITATIONS
244	Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019, 46, 483-491.	1.0	13
245	Calcium and vitamin D supplement intake may increase arterial stiffness in systemic lupus erythematosus patients. <i>Clinical Rheumatology</i> , 2019, 38, 1177-1186.	1.0	13
246	Interdisciplinary Care Model: Cardiovascular Diseases and Oral Health. <i>Computers in Health Care</i> , 2019, , 71-85.	0.2	0
247	Management of Prehypertension and Hypertension in Women of Childbearing Age. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 607-627.	0.1	0
248	Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort. <i>Clinical Rheumatology</i> , 2019, 38, 1139-1146.	1.0	3
249	Physical activity, sedentary behaviour and their associations with cardiovascular risk in systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 1128-1136.	0.9	23
250	Interaction between high-density lipoproteins and inflammation: Function matters more than concentration!. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 94-119.	6.6	50
251	Revealing the Interactions Between Diabetes, Diabetes-Related Diseases, and Cancers Based on the Network Connectivity of Their Related Genes. <i>Frontiers in Genetics</i> , 2020, 11, 617136.	1.1	1
252	Associations of metabolic syndrome in SLE. <i>Lupus Science and Medicine</i> , 2020, 7, e000436.	1.1	14
253	Type-I interferons in atherosclerosis. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	58
254	The role of aspirin in the primary prevention of accelerated atherosclerosis in systemic autoimmune rheumatic diseases. <i>Rheumatology</i> , 2020, 59, 3593-3602.	0.9	2
255	Management of cardiovascular disease in patients with systemic lupus erythematosus. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1617-1627.	0.9	16
256	Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2020, 39, 1725-1736.	1.0	7
257	Chronic inflammatory diseases, myocardial function and cardioprotection. <i>British Journal of Pharmacology</i> , 2020, 177, 5357-5374.	2.7	24
258	Mechanisms of vascular damage in systemic lupus erythematosus. , 2021, , 325-331.		0
259	Cardiovascular disease in systemic lupus erythematosus: an update. , 2021, , 415-426.		0
260	<i>CardioRheumatology</i> . , 2021, , 481-503.		0
261	<i>Cardiovascular Diseases and Rheumatology</i> . , 2021, , 353-381.		0

#	ARTICLE	IF	CITATIONS
262	Cardiovascular disease in lupus. , 2021, , 503-519.		0
263	Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention. <i>Inflammation</i> , 2021, 44, 1663-1682.	1.7	21
264	Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: A phenome-wide association study and inverse-variance weighted meta-analysis. <i>Lupus</i> , 2021, 30, 1264-1272.	0.8	2
265	Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus. <i>Revista Colombiana De ReumatologÃa</i> , 2021, 28, 21-30.	0.0	4
266	When and How Is It Possible to Stop Therapy in Patients with Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1909-1917.	2.2	10
267	QRISK3 relation to carotid plaque is higer than that of score in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 1408-1416.	0.9	8
268	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. <i>International Journal of Women's Dermatology</i> , 2021, 7, 560-575.	1.1	7
269	Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4427.	1.0	18
270	The brain in SLE. , 2021, , 231-255.		0
271	Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 605-613.	1.3	5
272	The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy. <i>Current Opinion in Rheumatology</i> , 2021, 33, 211-218.	2.0	9
273	Assessment of vascular stiffness using different modalities in patients with systemic lupus erythematosus: a case control study. <i>Egyptian Heart Journal</i> , 2020, 72, 24.	0.4	5
274	Evaluation of Ischemia Modified Albumin Levels and Carotid Intima Media Thickness in Patients with Systemic Lupus Eythematosus. <i>European Journal of Basic Medical Sciences</i> , 2014, 4, 77-82.	0.2	1
275	Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. <i>Current Vascular Pharmacology</i> , 2020, 18, 549-565.	0.8	61
276	Investigation of the Association Between Carotid Artery Intima-Media Thickness (IMT) and Cardiac Risk Factors in Patients with Systemic Lupus Erythematosus. <i>Current Rheumatology Reviews</i> , 2020, 16, 125-133.	0.4	4
277	Hyperhomocysteinemia and Lupus Nephritis. <i>Cureus</i> , 2019, 11, e5065.	0.2	5
278	Cardiovascular Disease in Patients With Systemic Lupus Erythematosus. <i>Cardiology in Review</i> , 2021, 29, 323-327.	0.6	3
279	Epidemiology of the Metabolic Syndrome. , 2005, , 109-129.		0

#	ARTICLE	IF	CITATIONS
280	Connective Tissue Diseases and the Heart. , 2007, , 2331-2356.		2
283	Subclinical Atherosclerosis in Systemic Autoimmune Disorders. , 0, , .		0
285	Atherogenesis and Vascular Disease in SLE. , 0, , .		0
286	Cardiovascular Risk in Rheumatic Disease. , 2013, , 505-514.		0
287	Atherosclerosis in Systemic Lupus Erythematosus â€“ Epidemiology, Risk Factors, Subclinical Assessment and Future Study. Rheumatology (Sunnyvale, Calif), 2013, s4, .	0.3	3
289	Impact of Endocrine Disorders on Autoimmune Diseases. Endocrinology, 2019, , 1-36.	0.1	0
290	Inflammation Injury and Selected Disease Processes Causing Aortic Root and Aortic Valvular Inflammation. Cardiovascular Medicine, 2020, , 51-70.	0.0	0
292	Treatment patterns and control of hypertension in systemic lupus erythematosus (SLE): a cross-sectional study. BMJ Open, 2021, 11, e048384.	0.8	1
293	Factors Associated With Self-Reported Capacity to Walk, Jog and Run in Individuals With Systemic Lupus Erythematosus. Archives of Rheumatology, 2021, 36, 89-100.	0.3	0
295	Jieduquyuziyan Prescription alleviates hepatic gluconeogenesis via PI3K/Akt/PGC-1Î± pathway in glucocorticoid-induced MRL/lpr mice. Journal of Ethnopharmacology, 2022, 284, 114815.	2.0	6
296	Impact of Endocrine Disorders on Autoimmune Diseases. Endocrinology, 2021, , 227-261.	0.1	1
299	Cardiovascular disease in systemic lupus erythematosus. Rheumatology and Immunology Research, 2021, 2, 157-172.	0.2	3
300	Cardiovascular Implications of Immune Disorders in Women. Circulation Research, 2022, 130, 593-610.	2.0	13
301	Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus. Lupus Science and Medicine, 2022, 9, e000564.	1.1	10
302	Assessment of subclinical atherosclerosis with carotid intima-media thickness in patients with scleroderma. Genel Tıp Dergisi, 2022, 32, 67-73.	0.1	0
303	Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome as Risk Factors for Acute Coronary Syndrome in Young Patients. Journal of Clinical Rheumatology, 2022, 28, 143-146.	0.5	1
304	Asymptomatic coronary artery disease assessed by coronary computed tomography in patients with systemic lupus erythematosus: A systematic review and meta-analysis. European Journal of Internal Medicine, 2022, 100, 102-109.	1.0	4
305	Endothelial function and endothelial progenitor cells in systemic lupus erythematosus. Nature Reviews Rheumatology, 2022, 18, 286-300.	3.5	18

#	ARTICLE	IF	CITATIONS
306	Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases. Journal of Inflammation Research, 2021, Volume 14, 6893-6906.	1.6	8
309	Hypertension in connective tissue disease. Journal of Human Hypertension, 2024, 38, 19-28.	1.0	0
311	Ramipril Improves Endothelial Function and Increases the Number of Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 0, Publish Ahead of Print, .	0.5	2
312	Quality of life measures and physical activity in childhood systemic lupus erythematosus. Lupus, 2022, 31, 1114-1120.	0.8	1
313	Insulin Resistance and Diabetes Mellitus in Patients with Systemic Lupus Erythematosus. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2023, 23, 503-514.	0.6	3
314	Outcomes Following Acute Coronary Syndrome in Patients With and Without Rheumatic Immune-Mediated Inflammatory Diseases. Journal of the American Heart Association, 2022, 11, .	1.6	5
315	Utilization of preventive services in a systemic lupus erythematosus population-based cohort: a Lupus Midwest Network (LUMEN) study. Arthritis Research and Therapy, 2022, 24, .	1.6	4
316	Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses. Clinical Rheumatology, 2022, 41, 3897-3913.	1.0	5
317	Comorbidities among Egyptian systemic lupus erythematosus: The COMOSLE-EGYPT study. Chronic Illness, 2023, 19, 791-803.	0.6	1
318	Increased risk of type 2 diabetes in patients with systemic lupus erythematosus: A nationwide cohort study in Taiwan. Medicine (United States), 2022, 101, e32520.	0.4	6
319	Risk of End-Stage Renal Disease in Patients With Systemic Lupus Erythematosus and Diabetes Mellitus: A Danish Nationwide Cohort Study. Arthritis Care and Research, 2023, 75, 1871-1877.	1.5	3
320	Características de la afección cardíaca de los pacientes con lupus eritematoso sistémico. Iatreia, 2013, 26, .	0.1	3
321	Menopausal hormone therapy in systemic lupus erythematosus: Pro et contra. Nauchno-Prakticheskaya Revmatologiya, 2023, 61, 70-76.	0.2	1
323	Atherosclerosis in Systemic Lupus Erythematosus. Current Atherosclerosis Reports, 2023, 25, 819-827.	2.0	2
326	Vascular damage in systemic lupus erythematosus. Nature Reviews Nephrology, 2024, 20, 251-265.	4.1	1